Lee Hyuk, Kim Jae J, Kim Jeong Hwan, Lee Jun Haeng, Son Hee Jung, Rhee Poong-Lyul, Rhee Jong Chul, Ko Young Hyeh
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Korean J Gastroenterol. 2006 Mar;47(3):205-12.
BACKGROUND/AIMS: Microsatellite instability (MSI) reflects the defect in DNA mismatch repair (MMR) pathways and plays an important role in certain malignancies. However, the role of MSI in the development of gastric B-cell lymphomas remains unsettled. We aimed to investigate the clinical significance of MSI in patients with gastric B-cell lymphoma.
Seven micosatellite loci (BAT25, BAT26, D2S123, D5S346, D17S250, D14S50, IGF-IIR) were used for MSI analyses. Microsatellite genotypes were categorized as microsatellite stable (MSS, no positive marker), low frequency MSI (MSI-L,<40% positive marker) and high frequency MSI (MSI-H, >40% positive marker). Among the gastric B-cell lymphoma patients who underwent MSI analysis between September 2002 and May 2003, twenty-two patients were enrolled. Median follow-up duration was 23 months (6-32 months).
Median age was 46 years (26-73 years). Male to female ratio was 1:1.4. Twelve patients (54.5%) underwent Helicobacter pylori (H. pylori) eradication and ten patients (45.5%) underwent chemoradiation therapy. No case presented MSI-H. MSI-L was observed in 40.9% (9/22). Between MSS group and MSI-L group, there was no significant difference in age, tumor stage, location, grade of large cell component, H. pylori infection, bulk of tumor and proportion of regression or recurrence. All positive markers belonged to the dinucleotide markers.
The current study suggests that the role of MSI is questionable in the development of gastric B-cell lymphoma due to their low incidence.
背景/目的:微卫星不稳定性(MSI)反映了DNA错配修复(MMR)途径的缺陷,在某些恶性肿瘤中起重要作用。然而,MSI在胃B细胞淋巴瘤发生发展中的作用仍未明确。我们旨在探讨MSI在胃B细胞淋巴瘤患者中的临床意义。
使用7个微卫星位点(BAT25、BAT26、D2S123、D5S346、D17S250、D14S50、IGF-IIR)进行MSI分析。微卫星基因型分为微卫星稳定(MSS,无阳性标记)、低频MSI(MSI-L,<40%阳性标记)和高频MSI(MSI-H,>40%阳性标记)。在2002年9月至2003年5月间接受MSI分析的胃B细胞淋巴瘤患者中,纳入了22例患者。中位随访时间为23个月(6 - 32个月)。
中位年龄为46岁(26 - 73岁)。男女比例为1:1.4。12例患者(54.5%)接受了幽门螺杆菌(H. pylori)根除治疗,10例患者(45.5%)接受了放化疗。无病例表现为MSI-H。40.9%(9/22)观察到MSI-L。在MSS组和MSI-L组之间,年龄、肿瘤分期、位置、大细胞成分分级、H. pylori感染、肿瘤体积以及消退或复发比例方面无显著差异。所有阳性标记均属于二核苷酸标记。
当前研究表明,由于MSI在胃B细胞淋巴瘤中发生率较低,其在胃B细胞淋巴瘤发生发展中的作用值得怀疑。